Pfizer

Summary

In 1849 was created Pfizer, which is appeared as Corporate Investor. The venture was found in North America in United States. The main office of represented Corporate Investor is situated in the New York.

The overall number of key employees were 3.

The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Pfizer, startups are often financed by Ysios Capital, Kurma Partners, Idinvest Partners. The meaningful sponsors for the fund in investment in the same round are OrbiMed, Canaan Partners, Takeda Ventures. In the next rounds fund is usually obtained by Pfizer Venture Investments, Life Sciences Partners, Bay City Capital.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. We can highlight the next thriving fund investment areas, such as Health Diagnostics, Pharmaceutical. The fund has specific favorite in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Allogene Therapeutics, NovoCure, Merus.

The real fund results show that this Corporate Investor is 12 percentage points more often commits exit comparing to other companies. The important activity for fund was in 2017. The higher amount of exits for fund were in 2019. The fund is constantly included in less than 2 investment rounds annually. Comparing to the other companies, this Pfizer performs on 5 percentage points less the average number of lead investments. The common things for fund are deals in the range of 10 - 50 millions dollars. The typical startup value when the investment from Pfizer is 100-500 millions dollars.